

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 1839


L1 SCREEN CREATED

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L2 SCREEN CREATED

=>

Uploading C:\Program Files\Stnexp\Queries\10560502.str



chain nodes :

10 13 14 15

ring nodes :

1 2 3 4 5 6 7 8 9

chain bonds :

10-13 13-14 13-15

ring bonds :

1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9

exact/norm bonds :

2-7 3-9 7-8 8-9 10-13 13-14 13-15

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS

11:Atom 13:CLASS 14:CLASS 15:Atom

Generic attributes :

15:

Number of Carbon Atoms : less than 7

Number of Hetero Atoms : 2 or more

Type of Ring System : Monocyclic

Element Count :

Node 15: Limited

C,C4

N,N2

O,O0

S,S0

L3 STRUCTURE UPLOADED

=> que L3 AND L1 NOT L2

L4 QUE L3 AND L1 NOT L2


=> d l4

L4 HAS NO ANSWERS

L1 SCR 1839

L2 SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L3 STR



Structure attributes must be viewed using STN Express query preparation.

L4 QUE L3 AND L1 NOT L2

=> s l4 sss sam

SAMPLE SEARCH INITIATED 18:02:05 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 6258 TO ITERATE

32.0% PROCESSED 2000 ITERATIONS

5 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 120417 TO 129903

PROJECTED ANSWERS: 75 TO 549

L5 5 SEA SSS SAM L3 AND L1 NOT L2

=> =>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 1839


L6 SCREEN CREATED

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L7 SCREEN CREATED

=>

Uploading C:\Program Files\Stnexp\Queries\10560502 (a).str



```

chain nodes :
10 13 14 15
ring nodes :
1 2 3 4 5 6 7 8 9 17 18 19 20 21 22 23 24 25 26 27 28
chain bonds :
10-13 13-14 13-15
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9 17-18 17-22 18-19 19-20 20-21
21-22 23-24 23-28 24-25 25-26 26-27 27-28
exact/norm bonds :
2-7 3-9 7-8 8-9 10-13 13-14 13-15 17-18 17-22 18-19 19-20 20-21 21-22
23-24 23-28 24-25 25-26 26-27 27-28

```

normalized bonds :
 1-2 1-6 2-3 3-4 4-5 5-6
 isolated ring systems :
 containing 1 : 17 : 23 :

G1:[*1],[*2]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
 11:Atom 13:CLASS 14:CLASS 15:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom
 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom

Element Count :

Node 15: Limited

C,C4
 N,N2
 O,O0
 S,S0

L8 STRUCTURE UPLOADED

=> que L8 AND L6 NOT L7

L9 QUE L8 AND L6 NOT L7

=> d l9

L9 HAS NO ANSWERS

L6 SCR 1839

L7 SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L8 STR

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.

L9 QUE L8 AND L6 NOT L7

=> s l9 sss sam

SAMPLE SEARCH INITIATED 18:05:17 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 208 TO ITERATE

100.0% PROCESSED 208 ITERATIONS

16 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 3295 TO 5025

PROJECTED ANSWERS: 80 TO 560

L10 16 SEA SSS SAM L8 AND L6 NOT L7

=> =>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 1839

L11 SCREEN CREATED

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L12 SCREEN CREATED

=>

Uploading C:\Program Files\Stnexp\Queries\10560502 (b).str



chain nodes :

```

10 13 14 15 34 35
ring nodes :
1 2 3 4 5 6 7 8 9 17 18 19 20 21 22 23 24 25 26 27 28
chain bonds :
10-13 13-14 13-15 19-34 25-35
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9 17-18 17-22 18-19 19-20 20-21
21-22 23-24 23-28 24-25 25-26 26-27 27-28
exact/norm bonds :
2-7 3-9 7-8 8-9 10-13 13-14 13-15 17-18 17-22 18-19 19-20 19-34 20-21
21-22 23-24 23-28 24-25 25-26 25-35 26-27 27-28
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 : 17 : 23 :
```

G1:[*1],[*2]

G2:O,S,CH3,Et,n-Pr,i-Pr,n-Bu,i-Bu,s-Bu,t-Bu,NH

Match level :

```

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:Atom 13:CLASS 14:CLASS 15:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom
22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 34:CLASS 35:CLASS
Element Count :
Node 15: Limited
```

```

C,C4
N,N2
O,O0
S,S0
```

L13 STRUCTURE UPLOADED

=> que L13 AND L11 NOT L12

L14 QUE L13 AND L11 NOT L12

=> d l14

L14 HAS NO ANSWERS

L11 SCR 1839

L12 SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L13 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

L14 QUE L13 AND L11 NOT L12

=> s l14 sss sam

SAMPLE SEARCH INITIATED 18:08:16 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 208 TO ITERATE

100.0% PROCESSED 208 ITERATIONS 7 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 3295 TO 5025
PROJECTED ANSWERS: 7 TO 298

L15 7 SEA SSS SAM L13 AND L11 NOT L12

=> => s l14 sss ful
FULL SEARCH INITIATED 18:08:50 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 4951 TO ITERATE

100.0% PROCESSED 4951 ITERATIONS 194 ANSWERS
SEARCH TIME: 00.00.01

L16 194 SEA SSS FUL L13 AND L11 NOT L12

=> => s l16
L17 4 L16

=> d l17 1-4 bib,ab,hitstr

L17 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:1176376 CAPLUS

DN 147:486429

TI Preparation of indazole compounds that inhibit one or more receptor, or non-receptor, tyrosine or serine/threonine kinase

IN Ericsson, Anna M.; Burchat, Andrew; Frank, Kristine E.; Calderwood, David J.; Abbott, Lily K.; Argiriadi, Maria A.; Borhani, David W.; Cusack, Kevin P.; Dixon, Richard W.; Gordon, Thomas D.; Mullen, Kelly D.; Talanian, Robert V.; Wu, Xiaoyun; Zhang, Xiaolei; Wang, Lu X.; Li, Biqin; Barberis, Claude E.; Wishart, Neil

PA Abbott Laboratories, USA

SO PCT Int. Appl., 266pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007117465	A2	20071018	WO 2007-US8307	20070402
	WO 2007117465	A3	20080828		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
	US 20070282101	A1	20071206	US 2007-731950	20070402
PRAI	US 2006-788553P	P	20060331		

OS MARPAT 147:486429

AB The title indazoles I [R1 = H, benzyl substituted with OMe, (un)substituted alkyl, etc.; R3 = H, halo, NH2, OH, etc.; R4 = H or NH2; R5 = H, NH2, NO2, halo, etc.; R6 = H, alkoxy, alkyl, benzo[b]thienyl, etc.; R7 = H, halo, NH2, alkenyl, etc.] that inhibit one or more receptor, or non-receptor, tyrosine or S/T kinase, were prepared and formulated. Thus, reacting thiocarbamate II with 2-(pyridin-2-yl)ethylamine afforded 39% III. The exemplified compds. I inhibit either COT or MK2 at concns. of 50 µM or below.


IT 953401-93-9P 953402-11-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of indazoles that inhibit one or more receptor, or non-receptor, tyrosine or serine/threonine kinase)

RN 953401-93-9 CAPLUS


CN 4-Pyrimidinecarboxamide, N-(7-benzo[b]thien-2-yl-1H-indazol-5-yl)-1,2,3,6-tetrahydro-2,6-dioxo- (CA INDEX NAME)




RN 953402-11-4 CAPLUS

CN 4-Pyrimidinecarboxamide, N-(7-benzo[b]thien-2-yl-1H-indazol-5-yl)hexahydro-2,6-dioxo-, (4R)- (CA INDEX NAME)

Absolute stereochemistry.



L17 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2006:1324379 CAPLUS
 DN 146:220118
 TI Development of Dihydropyridone Indazole Amides as Selective Rho-Kinase Inhibitors
 AU Goodman, Krista B.; Cui, Haifeng; Dowdell, Sarah E.; Gaitanopoulos, Dimitri E.; Ivy, Robert L.; Sehon, Clark A.; Stavenger, Robert A.; Wang, Gren Z.; Viet, Andrew Q.; Xu, Weiwei; Ye, Guosen; Semus, Simon F.; Evans, Christopher; Fries, Harvey E.; Jolivet, Larry J.; Kirkpatrick, Robert B.; Dul, Edward; Khandekar, Sanjay S.; Yi, Tracey; Jung, David K.; Wright, Lois L.; Smith, Gary K.; Behm, David J.; Bentley, Ross; Doe, Christopher P.; Hu, Erding; Lee, Dennis
 CS Departments of Medicinal Chemistry, Biology, and Drug Metabolism and Pharmacokinetics, Cardiovascular and Urogenital Center of Excellence in Drug Discovery, Departments of Computational, Analytical, and Structural Sciences, Gene Expression and Protein Biochemistry, High Throughput Chemistry, GlaxoSmithKline Pharmaceuticals, King of Prussia, PA, 19406, USA
 SO Journal of Medicinal Chemistry (2007) 50(1), 6-9
 CODEN: JMCMAR; ISSN: 0022-2623
 PB American Chemical Society
 DT Journal
 LA English
 OS CASREACT 146:220118
 AB Rho kinase (ROCK1) mediates vascular smooth muscle contraction and is a potential target for the treatment of hypertension and related disorders. Indazole amide 3 was identified as a potent and selective ROCK1 inhibitor but possessed poor oral bioavailability. Optimization of this lead resulted in the discovery of a series of dihydropyridones, exemplified by 13, with improved pharmacokinetic parameters relative to the initial lead. Indazole substitution played a critical role in decreasing clearance and improving oral bioavailability.
 IT 817194-38-0
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (development of oral dihydropyridone indazole amides as selective rho-kinase inhibitors)
 RN 817194-38-0 CAPLUS
 CN 5-Pyrimidinecarboxamide, 4-(4-fluorophenyl)-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)



RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/560,502

L17 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2006:75171 CAPLUS
 DN 144:150383
 TI Preparation of N-(indazol-5-yl)-5-pyrimidinecarboxamides derivatives as
 inhibitors of Rho-kinases
 IN Sehon, Clark A.; Lee, Dennis; Goodman, Krista B.; Wang, Gren Z.; Viet,
 Andrew Q.
 PA SmithKline Beecham Corporation, USA
 SO PCT Int. Appl., 72 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006009889	A1	20060126	WO 2005-US21559	20050617
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AI, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
EP 1756092	A1	20070228	EP 2005-760213	20050617
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV			
JP 2008503492	T	20080207	JP 2007-516801	20050617
US 20080125427	A1	20080529	US 2007-570083	20070817
PRAI US 2004-580423P	P	20040617		
WO 2005-US21559	P	20050617		

OS MARPAT 144:150383

AB Title compds. I [R8 = NH2 and derivs., (un)substituted hetero/aryl, cycloalkyl, etc.; R9, R10 = independently absent, H, alkyl; R1 = cyclo/alkyl, (un)substituted alkyl/hetero/aryl; R2 = H, alkyl; R6 = H; R4, R5, R7 = independently H, halo, alkyl; and their pharmaceutically acceptable salts and solvates] were prepared as Rho-kinase, particularly ROCK1 kinase, inhibitors. Thus, reacting 4-(methyloxy)benzenecarboximidam ide (preparation given) with 4-fluorobenzaldehyde and N-(1H-indazol-5-yl)-3-oxobutanamide in the presence of KOAc in DMSO at 100° for 3 h gave II in 32% yield. Most of the pyrimidines I were active inhibitors of ROCK1 kinase at concns. in the range of 10 µM to 0.8µM. I are useful for treating hypertension, Alzheimer's disease, chronic and congestive heart failure and ischemic angina (no data).


IT 817197-72-1P, 2-Amino-4-(4-fluorophenyl)-N-(1H-indazol-5-yl)-6-methyl-1,4-dihydro-5-pyrimidinecarboxamide 817197-78-7P, 4-(4-Fluorophenyl)-N-(1H-indazol-5-yl)-2,6-dimethyl-1,4-dihydro-5-pyrimidinecarboxamide 874118-89-5P, 4-(4-Fluorophenyl)-N-(1H-indazol-5-yl)-6-methyl-2-(phenylamino)-1,4-dihydro-5-pyrimidinecarboxamide 874119-92-3P, 2-Amino-4-(4-chlorophenyl)-N-(6-fluoro-1H-indazol-5-yl)-6-methyl-1,4-dihydro-5-pyrimidinecarboxamide 874119-93-4P, 4-(4-Chlorophenyl)-N-(6-fluoro-1H-indazol-5-yl)-2,6-dimethyl-1,4-dihydro-5-pyrimidinecarboxamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of indazolyl-pyrimidinecarboxamides derivs. as ROCK1 kinase inhibitors)


RN 817197-72-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-amino-4-(4-fluorophenyl)-1,4-dihydro-N-1H-indazol-5-yl-6-methyl- (CA INDEX NAME)



RN 817197-78-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-fluorophenyl)-1,4-dihydro-N-1H-indazol-5-yl-2,6-dimethyl- (CA INDEX NAME)



RN 874118-89-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-fluorophenyl)-1,4-dihydro-N-1H-indazol-5-yl-6-methyl-2-(phenylamino)- (CA INDEX NAME)

L17 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2004:1156450 CAPLUS
 DN 142:93847
 TI Preparation of N-indazolyl tetrahydropyrimidinecarboxamides as ROCK inhibitors
 IN Drewry, David Harold; Evans, Brian; Goodman, Krista B.; Green, Darren Victor Steven; Jung, David Kendall; Lee, Denis; Stavenger, Robert A.; Wad, Sjoerd Nicolaas
 PA Smithkline Beecham Corporation, USA; Wadman, Sjoerd Nicolaas
 SO PCT Int. Appl., 183 pp.
 CODEN: PIXXD2 Applicant's
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004112719	A2	20041229	WO 2004-US19692	20040618
	WO 2004112719	A3	20050407		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	EP 1633740	A2	20060315	EP 2004-755699	20040618
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR			
	JP 2007516173	T	20070621	JP 2006-517466	20040618
	US 20070099944	A1	20070503	US 2005-560502	20051213
PRAI	US 2003-479753P	P	20030619		
	WO 2004-US19692	W	20040618		
OS	MARPAT 142:93847				

AB The title compds. [I; X = O, S, alkyl, NHR; A = aryl, aralkyl, heteroaryl, alkyl, etc.; R = alkyl, aryl, heteroaryl, etc.; R1 = H, halo, alkyl, aryl, etc.; R2 = H, alkyl; R3 = H, alkyl, CH2OMe, aryl, heteroaryl; or R2 and R3 together with the ring and atoms to which they are attached form a fused ring system; R4, R5 = H, alkyl, aralkyl; R6 = H, halo; R7 = H, alkyl, halo] which are useful in the treatment of diseases associated with inappropriate ROCK-1 kinase, were prepared E.g., a 2-step synthesis of II, starting from 5-aminoindazole and diketene, was given. All exemplified compds. I (183 compds.) showed pIC50 of 5.0 or greater against Rock-1, and against Aurora-A kinase. The pharmaceutical composition comprising the compound


I is disclosed.

IT 817198-28-0P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of N-indazolyl tetrahydropyrimidinecarboxamides as ROCK inhibitors)

RN 817198-28-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3-bromophenyl)-1,2,3,4-tetrahydro-N-1H-indazol-

5-yl-6-methyl-2-oxo- (CA INDEX NAME)



IT	817194-38-0P	817194-46-0P	817194-52-8P
	817194-57-3P	817194-62-0P	817194-68-6P
	817194-73-3P	817194-78-8P	817194-84-6P
	817194-92-6P	817194-99-3P	817195-05-4P
	817195-11-2P	817195-16-7P	817195-19-0P
	817195-22-5P	817195-26-9P	817195-30-5P
	817195-37-2P	817195-43-0P	817195-48-5P
	817195-53-2P	817195-59-8P	817195-67-8P
	817195-73-6P	817195-81-6P	817195-87-2P
	817195-90-7P	817195-97-4P	817196-03-5P
	817196-06-8P	817196-11-5P	817196-14-8P
	817196-19-3P	817196-25-1P	817196-32-0P
	817196-38-6P	817196-46-6P	817196-55-7P
	817196-58-0P	817196-61-5P	817196-64-8P
	817196-68-2P	817196-76-2P	817196-82-0P
	817196-87-5P	817196-91-1P	817196-96-6P
	817197-01-6P	817197-06-1P	817197-11-8P
	817197-16-3P	817197-21-0P	817197-27-6P
	817197-33-4P	817197-39-0P	817197-45-8P
	817197-51-6P	817197-57-2P	817197-62-9P
	817197-66-3P	817197-72-1P	817197-78-7P
	817197-83-4P	817197-89-0P	817197-95-8P
	817197-99-2P	817198-03-1P	817198-07-5P
	817198-10-0P	817198-13-3P	817198-17-7P
	817198-20-2P	817198-22-4P	817198-25-7P
	817198-33-7P	817198-38-2P	817198-43-9P
	817198-50-8P	817198-58-6P	817198-61-1P
	817198-66-6P	817198-71-3P	817198-75-7P
	817198-82-6P	817198-86-0P	817198-90-6P
	817198-94-0P	817199-00-1P	817199-04-5P
	817199-08-9P	817199-12-5P	817199-16-9P
	817199-20-5P	817199-22-7P	817199-23-8P
	817199-25-0P	817199-26-1P	817199-27-2P
	817199-28-3P	817199-29-4P	817199-31-8P
	817199-32-9P	817199-33-0P	817199-34-1P
	817199-35-2P	817199-36-3P	817199-38-5P
	817199-39-6P	817199-40-9P	817199-41-0P
	817199-42-1P	817199-43-2P	817199-44-3P
	817199-46-5P	817199-47-6P	817199-48-7P
	817199-49-8P	817199-50-1P	817199-51-2P
	817199-52-3P	817199-53-4P	817199-54-5P


817199-55-6P 817199-57-8P 817199-59-0P
 817199-60-3P 817199-62-5P 817199-63-6P
 817199-64-7P 817199-65-8P 817199-66-9P
 817199-67-0P 817199-68-1P 817199-69-2P
 817199-70-5P 817199-71-6P 817199-72-7P
 817199-73-8P 817199-74-9P 817199-75-0P
 817199-76-1P 817199-77-2P 817199-79-4P
 817199-80-7P 817199-81-8P 817199-82-9P
 817199-83-0P 817199-84-1P 817199-85-2P
 817199-86-3P 817199-87-4P 817199-88-5P
 817199-90-9P 817199-91-0P 817199-92-1P
 817199-93-2P 817199-94-3P 817199-95-4P
 817199-96-5P 817199-98-7P 817200-00-3P
 817200-01-4P 817200-02-5P 817200-03-6P
 817200-04-7P 817200-05-8P 817200-06-9P
 817200-07-0P 817200-08-1P 817200-09-2P
 817200-10-5P 817200-11-6P 817200-12-7P
 817200-13-8P 817200-14-9P 817200-15-0P
 817200-16-1P 817200-17-2P 817200-52-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of N-indazolyl tetrahydropyrimidinecarboxamides as ROCK
 inhibitors)


RN 817194-38-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-fluorophenyl)-1,2,3,4-tetrahydro-N-1H-
 indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)




RN 817194-46-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3,4-diethoxyphenyl)-1,2,3,4-tetrahydro-N-1H-
 indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)




RN 817194-52-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-4-[4-(methanesulfonyl)phenyl]-2-oxo- (CA INDEX NAME)




RN 817194-57-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo-4-(3-thienyl)- (CA INDEX NAME)




RN 817194-62-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 1,2,3,4-tetrahydro-N-1H-indazol-5-yl-4,6-dimethyl-2-oxo- (CA INDEX NAME)




RN 817194-68-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-4-(1-naphthalenyl)-2-oxo- (CA INDEX NAME)




RN 817194-73-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-4-(2-naphthalenyl)-2-oxo- (CA INDEX NAME)




RN 817194-78-8 CAPLUS

CN Benzoic acid, 4-[1,2,3,4-tetrahydro-5-[(1H-indazol-5-ylamino)carbonyl]-6-methyl-2-oxo-4-pyrimidinyl]- (CA INDEX NAME)




RN 817194-84-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(2,4-difluorophenyl)-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)




RN 817194-92-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 1,2,3,4-tetrahydro-N-1H-indazol-5-yl-4-(3-methoxyphenyl)-6-methyl-2-oxo- (CA INDEX NAME)




RN 817194-99-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 1,2,3,4-tetrahydro-N-1H-indazol-5-yl-4-(2-methoxyphenyl)-6-methyl-2-oxo- (CA INDEX NAME)




RN 817195-05-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)




RN 817195-11-2 CAPLUS

CN Benzoic acid, 3-[1,2,3,4-tetrahydro-5-[(1H-indazol-5-ylamino)carbonyl]-6-methyl-2-oxo-4-pyrimidinyl]- (CA INDEX NAME)




RN 817195-16-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(2-fluorophenyl)-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)




RN 817195-19-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3-chloro-4-fluorophenyl)-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)




RN 817195-22-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 1,2,3,4-tetrahydro-4-[3-(2-hydroxyethoxy)phenyl]-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)




RN 817195-26-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-bromo-2-thienyl)-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)




RN 817195-30-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 1,2,3,4-tetrahydro-4-(4-hydroxyphenyl)-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)




RN 817195-37-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-chloro-2-fluorophenyl)-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)




RN 817195-43-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-4-[3-[(methylsulfonyl)amino]phenyl]-2-oxo- (CA INDEX NAME)




RN 817195-48-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo-4-(6-quinoxalinyloxy)- (CA INDEX NAME)




RN 817195-53-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[4-(aminosulfonyl)phenyl]-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)




RN 817195-59-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo-4-(2-quinolinyloxy)- (CA INDEX NAME)




RN 817195-67-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3-fluoro-4-methoxyphenyl)-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)




RN 817195-73-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3-cyanophenyl)-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)




RN 817195-81-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 1,2,3,4-tetrahydro-4-[4-(1H-imidazol-1-yl)phenyl]-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)




RN 817196-03-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-chlorophenyl)-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)




RN 817196-06-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[4-(acetylamino)phenyl]-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)




RN 817196-11-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(2-chlorophenyl)-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)




RN 817196-14-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(2,3-dihydro-1,4-benzodioxin-6-yl)-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)




RN 817196-19-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 1,2,3,4-tetrahydro-4-(3-hydroxyphenyl)-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)




RN 817196-25-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 1,2,3,4-tetrahydro-4-(8-hydroxy-2-quinolinyl)-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)




RN 817196-32-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3,4-dimethoxyphenyl)-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)




RN 817196-38-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[2-(4-chlorophenyl)ethyl]-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)




RN 817196-46-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 1,2,3,4-tetrahydro-4-[3-(1H-imidazol-1-yl)phenyl]-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)




RN 817196-64-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo-4-(4-pyridinyl)- (CA INDEX NAME)




RN 817196-68-2 CAPLUS

CN Benzoic acid, 3-[1,2,3,4-tetrahydro-5-[(1H-indazol-5-ylamino)carbonyl]-6-methyl-2-oxo-4-pyrimidinyl]-, methyl ester (CA INDEX NAME)




RN 817196-76-2 CAPLUS

CN Benzoic acid, 4-[1,2,3,4-tetrahydro-5-[(1H-indazol-5-ylamino)carbonyl]-6-methyl-2-oxo-4-pyrimidinyl]-, methyl ester (CA INDEX NAME)




RN 817197-11-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 1,2,3,4-tetrahydro-4-(2-hydroxy-4-methoxyphenyl)-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)




RN 817197-16-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[1,1'-biphenyl]-4-yl-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)




RN 817197-21-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-fluorophenyl)-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-(1-methylethyl)-2-oxo- (CA INDEX NAME)




RN 817197-27-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-fluorophenyl)-6-(2-furanyl)-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-2-oxo- (CA INDEX NAME)




RN 817197-33-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-fluorophenyl)-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-1,6-dimethyl-2-oxo- (CA INDEX NAME)




RN 817197-39-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 1,2,3,4-tetrahydro-N-1H-indazol-5-yl-1,6-dimethyl-4-(2-naphthalenyl)-2-oxo- (CA INDEX NAME)




RN 817197-45-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-4-(2-naphthalenyl)-2-thioxo- (CA INDEX NAME)




RN 817197-51-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-fluorophenyl)-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-thioxo- (CA INDEX NAME)




RN 817197-57-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-4-(3-thienyl)-2-thioxo- (CA INDEX NAME)




RN 817197-78-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-fluorophenyl)-1,4-dihydro-N-1H-indazol-5-yl-2,6-dimethyl- (CA INDEX NAME)




RN 817197-83-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-fluorophenyl)-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-N,6-dimethyl-2-oxo- (CA INDEX NAME)




RN 817197-89-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-fluorophenyl)-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-2-oxo- (CA INDEX NAME)




RN 817197-95-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 1-ethyl-4-(4-fluorophenyl)-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)




RN 817197-99-2 CAPLUS

CN 5-Pyrimidinecarboxamide, N-(3-amino-1H-indazol-5-yl)-4-(4-fluorophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo- (CA INDEX NAME)



RN 817198-03-1 CAPLUS


CN 5-Pyrimidinecarboxamide, 4-(2-benzofuranyl)-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)



RN 817198-07-5 CAPLUS


CN 5-Pyrimidinecarboxamide, 4-[(1E)-2-(2-furanyl)ethenyl]-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)

Double bond geometry as shown.




RN 817198-10-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-4-(5-methyl-2-furanyl)-2-oxo- (CA INDEX NAME)




RN 817198-13-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[5-(4-chlorophenyl)-2-furanyl]-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)




RN 817198-25-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo-4-(5-quinolinyl)- (CA INDEX NAME)



RN 817198-33-7 CAPLUS


CN 5-Pyrimidinecarboxamide, 1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo-4-(5-phenyl-2-thienyl)- (CA INDEX NAME)



RN 817198-38-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-4-[(1E)-2-(2-nitrophenyl)ethenyl]-2-oxo- (CA INDEX NAME)


Double bond geometry as shown.



RN 817198-43-9 CAPLUS


CN 5-Pyrimidinecarboxamide, 1,2,3,4-tetrahydro-N-1H-indazol-5-yl-4-[(1E)-2-(4-methoxyphenyl)ethenyl]-6-methyl-2-oxo- (CA INDEX NAME)

Double bond geometry as shown.



RN 817198-50-8 CAPLUS


CN 5-Pyrimidinecarboxamide, 4-(1-cyclohexen-1-yl)-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)



RN 817198-58-6 CAPLUS


CN 5-Pyrimidinecarboxamide, 1,2,3,4-tetrahydro-N-1H-indazol-5-yl-4-[(1E)-2-(2-methoxyphenyl)ethenyl]-6-methyl-2-oxo- (CA INDEX NAME)

Double bond geometry as shown.



RN 817198-61-1 CAPLUS


CN 5-Pyrimidinecarboxamide, 4-(2,2-diphenylethenyl)-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)



RN 817198-66-6 CAPLUS


CN 5-Pyrimidinecarboxamide, 4-[(1Z)-1-chloro-2-phenylethenyl]-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)

Double bond geometry as shown.




RN 817198-71-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo-4-[(phenylmethoxy)methyl]- (CA INDEX NAME)




RN 817198-75-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo-4-(2-phenylethynyl)- (CA INDEX NAME)




RN 817198-82-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[2,2'-bithiophen]-5-yl-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)




RN 817198-86-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-4-(3-methylbenzo[b]thien-2-yl)-2-oxo- (CA INDEX NAME)




RN 817199-04-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo-4-[3-(phenylmethoxy)phenyl]- (CA INDEX NAME)




RN 817199-08-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(9H-fluoren-2-yl)-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)




RN 817199-12-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3-bromo-4-fluorophenyl)-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)




RN 817199-16-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 1,2,3,4-tetrahydro-N-1H-indazol-5-yl-4-(7-methoxy-1,3-benzodioxol-5-yl)-6-methyl-2-oxo- (CA INDEX NAME)




RN 817199-20-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(1,3-benzodioxol-4-yl)-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)




RN 817199-22-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo-4-[3-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 817199-23-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo-4-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 817199-25-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 1,2,3,4-tetrahydro-4-(3-hydroxy-4-methoxyphenyl)-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)




RN 817199-26-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(5-chloro-1,3-benzodioxol-4-yl)-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)




RN 817199-27-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo-4-[5-(2-pyridinyl)-2-thienyl]- (CA INDEX NAME)




RN 817199-28-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo-4-(2-phenyl-4-thiazolyl)- (CA INDEX NAME)




RN 817199-29-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-4-[5-(methylthio)-2-thienyl]-2-oxo- (CA INDEX NAME)




RN 817199-31-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(2-benzothiazolyl)-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)




RN 817199-32-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(2H-1-benzopyran-3-yl)-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)




RN 817199-33-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo-4-[5-(2-phenylethynyl)-2-thienyl]- (CA INDEX NAME)




RN 817199-34-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo-4-[4-(2-phenylethynyl)-2-thienyl]- (CA INDEX NAME)




RN 817199-35-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-4-(5-methyl-2-thienyl)-2-oxo- (CA INDEX NAME)




RN 817199-36-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-4-[5-[1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]-2-thienyl]-2-oxo- (CA INDEX NAME)




RN 817199-38-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo-4-[4-(2-pyridinyl)phenyl]- (CA INDEX NAME)




RN 817199-39-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[4-(dimethylamino)phenyl]-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)





RN 817199-40-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[4-(diethylamino)phenyl]-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)




RN 817199-41-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(2-chloro-3-quinolinyl)-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)




RN 817199-42-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3,4-dihydro-4-methyl-2H-1,4-benzoxazin-7-yl)-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)




RN 817199-43-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-4-[4-(4-morpholinyl)phenyl]-2-oxo- (CA INDEX NAME)




RN 817199-44-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo-4-[4-(2-thienyl)phenyl]- (CA INDEX NAME)




RN 817199-46-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo-4-[4-(1H-pyrazol-1-yl)phenyl]- (CA INDEX NAME)




RN 817199-47-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo-4-[4-(1H-1,2,4-triazol-1-yl)phenyl]- (CA INDEX NAME)




RN 817199-48-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[2,3-difluoro-4-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)




RN 817199-49-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[4-(1H-benzimidazol-1-yl)phenyl]-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)




RN 817199-50-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-fluorophenyl)-N-[3-(4-fluorophenyl)-1H-indazol-5-yl]-1,2,3,4-tetrahydro-6-methyl-2-oxo- (CA INDEX NAME)




RN 817199-51-2 CAPLUS

CN 5-Pyrimidinecarboxamide, N-(3-chloro-1H-indazol-5-yl)-4-(4-fluorophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo- (CA INDEX NAME)




RN 817199-52-3 CAPLUS

CN 5-Pyrimidinecarboxamide, N-(3-chloro-1H-indazol-5-yl)-1,2,3,4-tetrahydro-6-methyl-4-(2-naphthalenyl)-2-oxo- (CA INDEX NAME)




RN 817199-53-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-fluorophenyl)-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-2-oxo-6-propyl- (CA INDEX NAME)




RN 817199-54-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 1,2,3,4-tetrahydro-N-1H-indazol-5-yl-4-(2-naphthalenyl)-2-oxo-6-propyl- (CA INDEX NAME)




RN 817199-55-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-fluorophenyl)-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-(methoxymethyl)-2-oxo- (CA INDEX NAME)




RN 817199-57-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-4-(3-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 817199-59-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3-aminophenyl)-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)




RN 817199-60-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3,5-dibromophenyl)-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)



RN 817199-62-5 CAPLUS


CN 5-Pyrimidinecarboxamide, 4-(3,4-difluorophenyl)-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)



RN 817199-63-6 CAPLUS


CN 5-Pyrimidinecarboxamide, 1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-4-[(1E)-1-methyl-2-phenylethenyl]-2-oxo- (CA INDEX NAME)

Double bond geometry as shown.




RN 817199-64-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 6-(4-fluorophenyl)-1,2,3,6-tetrahydro-N-1H-indazol-5-yl-1,4-dimethyl-2-oxo- (CA INDEX NAME)




RN 817199-65-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 6-ethyl-4-(4-fluorophenyl)-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-2-oxo- (CA INDEX NAME)




RN 817199-66-9 CAPLUS

CN 5-Pyrimidinecarboxamide, N-(6-chloro-1H-indazol-5-yl)-4-(4-fluorophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo- (CA INDEX NAME)




RN 817199-67-0 CAPLUS

CN 5-Pyrimidinecarboxamide, N-(6-chloro-1H-indazol-5-yl)-1,2,3,4-tetrahydro-6-methyl-4-(2-naphthalenyl)-2-oxo- (CA INDEX NAME)




RN 817199-68-1 CAPLUS

CN 5-Pyrimidinecarboxamide, N-(6-fluoro-1H-indazol-5-yl)-4-(4-fluorophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo- (CA INDEX NAME)




RN 817199-69-2 CAPLUS

CN 5-Pyrimidinecarboxamide, N-(7-chloro-1H-indazol-5-yl)-4-(4-fluorophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo- (CA INDEX NAME)




RN 817199-70-5 CAPLUS

CN 5-Pyrimidinecarboxamide, N-(7-chloro-1H-indazol-5-yl)-1,2,3,4-tetrahydro-6-methyl-4-(2-naphthalenyl)-2-oxo- (CA INDEX NAME)




RN 817199-71-6 CAPLUS

CN 5-Pyrimidinecarboxamide, N-(3-bromo-1H-indazol-5-yl)-4-(4-fluorophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo- (CA INDEX NAME)




RN 817199-72-7 CAPLUS

CN 5-Pyrimidinecarboxamide, N-(3-bromo-1H-indazol-5-yl)-1,2,3,4-tetrahydro-6-methyl-4-(2-naphthalenyl)-2-oxo- (CA INDEX NAME)




RN 817199-73-8 CAPLUS

CN 5-Pyrimidinecarboxamide, N-(3-bromo-1H-indazol-5-yl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-4-(3-thienyl)- (CA INDEX NAME)




RN 817199-74-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-bromophenyl)-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)




RN 817199-75-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3'-amino[1,1'-biphenyl]-4-yl)-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)




RN 817199-76-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo-4-[4-(3-thienyl)phenyl]- (CA INDEX NAME)




RN 817199-77-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(2',4'-difluoro[1,1'-biphenyl]-4-yl)-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)




RN 817199-79-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 1,2,3,4-tetrahydro-N-1H-indazol-5-yl-4-(4'-methoxy[1,1'-biphenyl]-4-yl)-6-methyl-2-oxo- (CA INDEX NAME)




RN 817199-80-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4'-chloro[1,1'-biphenyl]-4-yl)-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)




RN 817199-81-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3'-acetyl[1,1'-biphenyl]-4-yl)-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)




RN 817199-82-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3'-chloro[1,1'-biphenyl]-4-yl)-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)




RN 817199-83-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[4-(1,3-benzodioxol-5-yl)phenyl]-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)




RN 817199-84-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo-4-[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)




RN 817199-85-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(2'-chloro[1,1'-biphenyl]-4-yl)-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)




RN 817199-86-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[4'-(dimethylamino)[1,1'-biphenyl]-4-yl]-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)




RN 817199-87-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4'-fluoro[1,1'-biphenyl]-4-yl)-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)




RN 817199-88-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 1,2,3,4-tetrahydro-N-1H-indazol-5-yl-4-(2'-methoxy[1,1'-biphenyl]-4-yl)-6-methyl-2-oxo- (CA INDEX NAME)




RN 817199-90-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 1,2,3,4-tetrahydro-N-1H-indazol-5-yl-4-(3'-methoxy[1,1'-biphenyl]-4-yl)-6-methyl-2-oxo- (CA INDEX NAME)




RN 817199-91-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 1,2,3,4-tetrahydro-N-1H-indazol-5-yl-4-[4-(1H-indol-5-yl)phenyl]-6-methyl-2-oxo- (CA INDEX NAME)




RN 817199-92-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[4-(3,5-dimethyl-4-isoxazolyl)phenyl]-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)




RN 817199-93-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo-4-[4-(1H-pyrazol-4-yl)phenyl]- (CA INDEX NAME)




RN 817199-94-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[3',5'-bis(trifluoromethyl)-1,1'-biphenyl]-4-yl]-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)




RN 817199-95-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[2-fluoro-4-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)




RN 817199-96-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[2-fluoro-3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)




RN 817199-98-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(2,6-difluorophenyl)-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)




RN 817200-00-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3'-amino[1,1'-biphenyl]-3-yl)-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)




RN 817200-01-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(2',4'-difluoro[1,1'-biphenyl]-3-yl)-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)




RN 817200-02-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[1,1'-biphenyl]-3-yl-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)




RN 817200-03-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo-4-[3-(3-thienyl)phenyl]- (CA INDEX NAME)




RN 817200-04-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo-4-[5-[4-(trifluoromethyl)phenyl]-2-thienyl]- (CA INDEX NAME)




RN 817200-05-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[5-(4-chlorophenyl)-2-thienyl]-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)




RN 817200-06-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 1,2,3,4-tetrahydro-N-1H-indazol-5-yl-4-[5-(4-methoxyphenyl)-2-thienyl]-6-methyl-2-oxo- (CA INDEX NAME)




RN 817200-07-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[2,3'-bithiophen]-5-yl-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)



RN 817200-08-1 CAPLUS


CN 5-Pyrimidinecarboxamide, 1,2,3,4-tetrahydro-6-methyl-N-(3-methyl-1H-indazol-5-yl)-4-(2-naphthalenyl)-2-oxo- (CA INDEX NAME)



RN 817200-09-2 CAPLUS


CN 5-Pyrimidinecarboxamide, 4-(3,5-difluorophenyl)-N-[3-[(3-methyl-1H-indazol-5-yl)-2-oxo-1,2,3,4-tetrahydro-6-methyl-N-1H-indazol-5-yl]-2-naphthalenyl]-2-oxo- (CA INDEX NAME)

fluorophenyl)amino]-1H-indazol-5-yl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-
(CA INDEX NAME)




RN 817200-10-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3,5-difluorophenyl)-N-[3-[(3,5-difluorophenyl)amino]-1H-indazol-5-yl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-
(CA INDEX NAME)



RN 817200-11-6 CAPLUS


CN 5-Pyrimidinecarboxamide, 4-(3,4-difluorophenyl)-N-[3-[(3,5-difluorophenyl)amino]-1H-indazol-5-yl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-
(CA INDEX NAME)



RN 817200-12-7 CAPLUS


CN 5-Pyrimidinecarboxamide, 4-(3,4-difluorophenyl)-N-[3-[(3,4-difluorophenyl)amino]-1H-indazol-5-yl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-
(CA INDEX NAME)

fluorophenyl)amino]-1H-indazol-5-yl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-
(CA INDEX NAME)




RN 817200-13-8 CAPLUS

CN 5-Pyrimidinecarboxamide, N-[3-[(3,5-difluorophenyl)amino]-1H-indazol-5-yl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-4-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 817200-14-9 CAPLUS


CN 5-Pyrimidinecarboxamide, 4-(4-chloro-2-fluorophenyl)-N-[3-[(3,5-difluorophenyl)amino]-1H-indazol-5-yl]-1,2,3,4-tetrahydro-6-methyl-2-oxo- (CA INDEX NAME)



RN 817200-15-0 CAPLUS


CN 5-Pyrimidinecarboxamide, 4-(3,5-difluorophenyl)-N-[3-[(4-chloro-2-fluorophenyl)amino]-1H-indazol-5-yl]-1,2,3,4-tetrahydro-6-methyl-2-oxo- (CA INDEX NAME)

fluorophenyl)amino]-1H-indazol-5-yl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-
(CA INDEX NAME)




RN 817200-16-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3,4-difluorophenyl)-N-[3-[(4-fluorophenyl)amino]-1H-indazol-5-yl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-
(CA INDEX NAME)




RN 817200-17-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3,5-difluorophenyl)-N-[3-[(4-fluorophenyl)amino]-1H-indazol-5-yl]-1,2,3,4-tetrahydro-6-methyl-2-oxo- (CA INDEX NAME)



RN 817200-52-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(5-chloro-2-thienyl)-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)




IT 817200-34-3P 817200-40-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-indazolyl tetrahydropyrimidinecarboxamides as ROCK inhibitors)


RN 817200-34-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 6-(4-fluorophenyl)-1,6-dihydro-N-1H-indazol-5-yl-2-methoxy-1,4-dimethyl- (CA INDEX NAME)



RN 817200-40-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(5-bromo-2-thienyl)-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo- (CA INDEX NAME)



10/560,502

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

22.28

205.91

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-3.20

-3.20

STN INTERNATIONAL LOGOFF AT 18:09:35 ON 26 SEP 2008